Vanda Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $50,474 | $47,462 | $45,271 | $38,815 |
Gross Profit | 45,989 | 42,004 | 41,811 | 35,752 |
EBITDA | -8,178 | -7,011 | -5,936 | -5,615 |
EBIT | -10,146 | -9,235 | -7,094 | -6,195 |
Net Income | -4,518 | -4,146 | -2,400 | 137 |
Net Change In Cash | 50,474 | 47,462 | 45,271 | 38,815 |
Free Cash Flow | -7,036 | 7,562 | -3,985 | -2,074 |
Cash | 102,953 | 125,158 | 135,821 | 183,186 |
Basic Shares | 58,220 | 57,760 | 57,532 | 57,595 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $192,640 | $254,382 | $268,682 | $248,168 |
Gross Profit | 192,640 | 230,100 | 243,053 | 224,804 |
EBITDA | -13,952 | 7,845 | 43,643 | 30,103 |
EBIT | -13,952 | 5,112 | 40,802 | 27,239 |
Net Income | 2,509 | 6,275 | 33,152 | 23,337 |
Net Change In Cash | 192,640 | 254,382 | 268,682 | 248,168 |
Cost of Revenue | 82,643 | -8,932 | 15,910 | |
Free Cash Flow | 12,418 | 31,305 | 63,662 | 49,980 |
Cash | 135,821 | 135,029 | 52,071 | 61,031 |
Basic Shares | 57,557 | 56,983 | 56,921 | 55,190 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.08 |
2024-03-31 | -$0.07 |
2023-12-31 | -$0.04 |
2023-09-30 | $0.002 |
